| Literature DB >> 20153925 |
Emma Bell1, Lindi Chen, Tao Liu, Glenn M Marshall, John Lunec, Deborah A Tweddle.
Abstract
The MYCN oncogene encodes a transcription factor which is amplified in up to 40% of high risk neuroblastomas. MYCN amplification is a well-established poor prognostic marker in neuroblastoma, however the role of MYCN expression and the mechanisms by which it acts to promote an aggressive phenotype remain largely unknown. This review discusses the current evidence identifying the direct and indirect downstream transcriptional targets of MYCN from recent studies, with particular reference to how MYCN affects the cell cycle, DNA damage response, differentiation and apoptosis in neuroblastoma. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20153925 DOI： 10.1016/j.canlet.2010.01.015
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679